Thiotepa Riemser Evrópusambandið - íslenska - EMA (European Medicines Agency)

thiotepa riemser

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - Æxlishemjandi lyf - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Teriflunomide Mylan Evrópusambandið - íslenska - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomide - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Glybera Evrópusambandið - íslenska - EMA (European Medicines Agency)

glybera

uniqure biopharma b.v.  - alipogene tiparvovec - hyperlipoproteinemia type i - lipid breytandi lyf - glybera er ætlað til fullorðinna sjúklinga sem greinast með ættgengri lípópróteinlipasa skort (lpld) og þjást af alvarlegum eða mörgum brisbólguárásum þrátt fyrir mataræði. greining lpld þarf að staðfesta með erfðafræðilegri prófun. vísbendingin er takmörkuð við sjúklinga með greinanlegan magn af lpl próteinum.

Monofer Innrennslislyf, lausn 100 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

monofer innrennslislyf, lausn 100 mg/ml

pharmacosmos a/s* - ferricum derisomaltosum inn - innrennslislyf, lausn - 100 mg/ml

Amlodipin Bluefish Tafla 10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

amlodipin bluefish tafla 10 mg

bluefish pharmaceuticals ab - amlodipinum besýlat - tafla - 10 mg

Amlodipin Bluefish Tafla 5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

amlodipin bluefish tafla 5 mg

bluefish pharmaceuticals ab - amlodipinum besýlat - tafla - 5 mg

Esomeprazole Jubilant Magasýruþolin tafla 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

esomeprazole jubilant magasýruþolin tafla 20 mg

jubilant pharmaceuticals nv - esomeprazolum magnesíum - magasýruþolin tafla - 20 mg

Esomeprazole Jubilant Magasýruþolin tafla 40 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

esomeprazole jubilant magasýruþolin tafla 40 mg

jubilant pharmaceuticals nv - esomeprazolum magnesíum - magasýruþolin tafla - 40 mg

Clopidogrel/Acetylsalicylic acid Teva Evrópusambandið - íslenska - EMA (European Medicines Agency)

clopidogrel/acetylsalicylic acid teva

teva pharma b.v. - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - sturtu - eftir að/asetýlsalisýlsýru mg er ætlað til að fyrirbyggja atherothrombotic atburðum í fullorðinn sjúklinga þegar þú tekur bæði eftir og asetýlsalisýlsýru (asa). eftir að/asetýlsalisýlsýru mg er fastur‑skammt samsetning lyf fyrir áframhaldandi meðferð í:ekki l hækkun bráð kransæðastíflu (óstöðug hálsbólgu eða ekki q‑bylgja kransæðastíflu) þar á meðal sjúklinga gangast undir stoðneti staðsetningar eftir stungið kransæðastíflu interventionst hækkun, bráð myndun stíflufleygs í læknisfræðilega sjúklingum rétt fyrir segaleysandi meðferð.

Thalidomide BMS (previously Thalidomide Celgene) Evrópusambandið - íslenska - EMA (European Medicines Agency)

thalidomide bms (previously thalidomide celgene)

bristol-myers squibb pharma eeig - dauða - mergæxli - Ónæmisbælandi lyf - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.